# EDGAR Filing Document

**Accession Number:** 0001714899
**File Stem:** 0001714899-26-000049
**Filing Date:** 2026-4
**Character Count:** 7927
**Document Hash:** 9762dce050dce7049c2c4b4d29356710
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001714899-26-000049.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001714899-26-000049

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260410

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Chin Peter Scott
- **CENTRAL INDEX KEY:** 0002124755

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38311
- **FILM NUMBER:** 26876424

**MAIL ADDRESS:**
- **STREET 1:** C/O DENALI THERAPEUTICS INC.
- **STREET 2:** 161 OYSTER POINT BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Denali Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001714899
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463872213
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 161 OYSTER POINT BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 866-8547

**MAIL ADDRESS:**
- **STREET 1:** 161 OYSTER POINT BLVD.
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

## Ex-24

![](peter_chinxpowerxofxatto001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Denali Therapeutics Inc. (the "Company"), hereby constitutes and appoints Ryan J. Watts, Alexander Schuth, and Tyler Nielsen, and each of them, as the undersigned's true and lawful attorney-in-fact to: 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in- fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of April, 2026. Signature: _____________________________ Print Name: Peter Chin

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Chin Peter Scott<br><sub>(Last) (First) (Middle)</sub><br>C/O DENALI THERAPEUTICS INC.<br>161 OYSTER POINT BOULEVARD, SECOND FLOOR<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Denali Therapeutics Inc. [ DNLI ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-04-10 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 170612<sup>(1)(2)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(3)</sup> | 2029-05-10 | Common Stock | 43000 | $22.31 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2030-02-10 | Common Stock | 35100 | $24.81 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2031-01-10 | Common Stock | 14250 | $80.03 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2032-01-03 | Common Stock | 13000 | $47.27 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2032-02-03 | Common Stock | 10250 | $33.74 | D |  |
| Stock Option (right to buy) | <sup>(4)</sup> | 2033-01-03 | Common Stock | 32900 | $27.63 | D |  |
| Stock Option (right to buy) | <sup>(5)</sup> | 2034-01-03 | Common Stock | 44750 | $20.33 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2035-01-03 | Common Stock | 40650 | $21.26 | D |  |
| Stock Option (right to buy) | <sup>(7)</sup> | 2036-03-20 | Common Stock | 63800 | $20.17 | D |  |

---

### Footnotes:

(1) Includes 2,326 shares acquired under the Denali ESPP.

(2) Includes 145,845 Unvested RSU's.

(3) The shares subject to the option are fully vested and exercisable.

(4) 25% of the shares subject to the option vested on January 3, 2024 and an additional 1/48 of the shares vested monthly thereafter.

(5) 25% of the shares subject to the option vested on January 3, 2025 and an additional 1/48 of the shares vest monthly thereafter.

(6) 25% of the shares subject to the option vested on January 3, 2026 and an additional 1/48 of the shares vest monthly thereafter.

(7) 25% of the shares subject to the option will vest on January 3, 2027 and an additional 1/48 of the shares vest monthly thereafter.

**Signature:** /s/ Tyler Nielsen, by power of attorney  
**Date:** 2026-04-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**